Artelo Biosciences Statistics
Share Statistics
Artelo Biosciences has 3.23M shares outstanding. The number of shares has increased by 1.21% in one year.
| Shares Outstanding | 3.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.20M |
| Failed to Deliver (FTD) Shares | 703 |
| FTD / Avg. Volume | 2.69% |
Short Selling Information
The latest short interest is 19.93K, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 19.93K |
| Short % of Shares Out | 0.62% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 1.65 |
Valuation Ratios
The PE ratio is -0.83 and the forward PE ratio is -1.33.
| PE Ratio | -0.83 |
| Forward PE | -1.33 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.42 |
| P/FCF Ratio | -1.02 |
| PEG Ratio | n/a |
Enterprise Valuation
Artelo Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 18.36, with a Debt / Equity ratio of 0.
| Current Ratio | 18.36 |
| Quick Ratio | 18.36 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.32 |
| Cash Flow / Debt | -127.11 |
| Interest Coverage | -2057.4 |
Financial Efficiency
Return on equity (ROE) is -0.51% and return on capital (ROIC) is -51.75%.
| Return on Equity (ROE) | -0.51% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -51.75% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.97M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -209.00K |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by -17.78% in the last 52 weeks. The beta is 1.35, so Artelo Biosciences 's price volatility has been higher than the market average.
| Beta | 1.35 |
| 52-Week Price Change | -17.78% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 46.46 |
| Average Volume (20 Days) | 26.12K |
Income Statement
In the last 12 months, Artelo Biosciences had revenue of $0 and earned -$9.87M in profits. Earnings per share was $-3.49.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -10.29M |
| Net Income | -9.87M |
| EBITDA | -10.29M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.49 |
Balance Sheet
The company has $6.89M in cash and $63.00K in debt, giving a net cash position of $6.83M.
| Cash & Cash Equivalents | 6.89M |
| Total Debt | 63.00K |
| Net Cash | 6.83M |
| Retained Earnings | -31.02M |
| Total Assets | 15.50M |
| Working Capital | 12.51M |
Cash Flow
In the last 12 months, operating cash flow was -$8.01M and capital expenditures $0, giving a free cash flow of -$8.01M.
| Operating Cash Flow | -8.01M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.01M |
| FCF Per Share | -2.83 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ARTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -314.41% |
| FCF Yield | -223.52% |
Analyst Forecast
The average price target for ARTL is $6, which is 440.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 440.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 10, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 10, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -2.2 |
| Piotroski F-Score | 2 |